Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) will host a conference call on November 5, 2021, at 8:30 a.m. ET, to discuss its third quarter 2021 financial results and corporate updates. Interested parties can join the call by dialing (866) 595-4538 domestically or (636) 812-6496 internationally, referencing conference ID 3287324. A webcast will be available on their website, with an archived replay accessible for 30 days.

Syros focuses on developing gene expression medicines and has a promising clinical pipeline, including treatments for various hematologic malignancies.

Positive

• Advancing a robust clinical-stage pipeline including treatments for myelodysplastic syndrome and acute myeloid leukemia.
• Focus on innovative approaches to control gene expression for targeted therapies.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and provide a corporate update.

To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international) and refer to conference ID 3287324. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005005/en/

Media Contact

Courtney Solberg

Syros Pharmaceuticals

917-698-9253

csolberg@syros.com

Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

What time is Syros Pharmaceuticals' third quarter 2021 earnings call?

The third quarter 2021 earnings call for Syros Pharmaceuticals is scheduled for 8:30 a.m. ET on November 5, 2021.

How can I access the Syros Pharmaceuticals earnings call?

You can access the Syros Pharmaceuticals earnings call by dialing (866) 595-4538 (domestic) or (636) 812-6496 (international), using conference ID 3287324.

What are the main therapeutic areas Syros Pharmaceuticals is focusing on?

Syros Pharmaceuticals is focusing on gene expression medicines for conditions such as myelodysplastic syndrome, acute myeloid leukemia, and acute promyelocytic leukemia.

Where can I find the webcast for the Syros Pharmaceuticals call?

The webcast for the Syros Pharmaceuticals call will be available on the Investors & Media section of their website at www.syros.com.